Application of autologous platelet-rich plasma (PRP), especially leukocyte- and platelet-rich fibrin (L-PRF), has emerged as a promising adjuvant therapy for the treatment of diabetic foot ulcers (DFUs). Conflicting results of PRP efficacy can be attributed to the lack of standardization in the PRP preparation process in addition to a paucity of well-designed randomized clinic trials (RCTs).
基金：
Tongji hospital in Huazhong University of Science and Technology [2201103295]; National Natural Science Foundation of China [82070859, 81100581]; Bethune Merck Diabetes Research Fund [2018]; Cardiac Rehabilitation and Metabolic Therapy Research Fund [2018]
第一作者单位：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Internal Med, Div Endocrinol, Wuhan 430030, Peoples R China
通讯作者：
通讯机构：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Internal Med, Div Endocrinol, Wuhan 430030, Peoples R China[3]Huazhong Univ Sci & Technol, Tongji Hosp, Lab Endocrinol, Wuhan 430030, Peoples R China
推荐引用方式(GB/T 7714)：
Shao Shiying,Pan Ruping,Chen Yong.Autologous Platelet-Rich Plasma for Diabetic Foot Ulcer[J].TRENDS IN ENDOCRINOLOGY AND METABOLISM.2020,31(12):885-890.doi:10.1016/j.tem.2020.10.003.
APA：
Shao, Shiying,Pan, Ruping&Chen, Yong.(2020).Autologous Platelet-Rich Plasma for Diabetic Foot Ulcer.TRENDS IN ENDOCRINOLOGY AND METABOLISM,31,(12)
MLA：
Shao, Shiying,et al."Autologous Platelet-Rich Plasma for Diabetic Foot Ulcer".TRENDS IN ENDOCRINOLOGY AND METABOLISM 31..12(2020):885-890
：
医学